Table 1 Patients’ characteristics according to liver function. (To be placed after ‘Results’ subsection ‘Patient’s characteristics’)
Characteristics | Na | Preserved Liver Function,b N = 143 | Reduced Liver Function,cN = 60 | p-valued | q-valuee |
|---|---|---|---|---|---|
Center, n / N (%) | 203 | < 0.001 | < 0.001 | ||
Lyon (n = 48) | 13 / 143 (9.0%) | 35 / 60 (58.0%) | |||
Rochester (n = 155) | 130 / 143 (91.0%) | 25 / 60 (42.0%) | |||
Age, Mean (SD) (years) | 203 | 58.5 (12.6) | 58.0 (10.0) | 0.3 | 0.4 |
Age Group, n / N (%) | 203 | 0.029 | 0.049 | ||
< 40 years | 12 / 143 (8.4%) | 4 / 60 (6.7%) | |||
40–65 years | 80 / 143 (56.0%) | 45 / 60 (75.0%) | |||
> 65 years | 51 / 143 (35.6%) | 11 / 60 (18.3%) | |||
Sex, n / N (%) | 203 | 0.13 | 0.2 | ||
female | 53 / 143 (37.0%) | 15 / 60 (25.0%) | |||
male | 90 / 143 (63.0%) | 45 / 60 (75.0%) | |||
Ethnicity | 203 | 0.3 | 0.4 | ||
Black | 5 / 143 (3.5%) | 0 / 60 (0%) | |||
Non-black | 138 / 143 (96.5%) | 60 / 60 (100%) | |||
Height (cm), Mean (SD) | 203 | 171.1 (10.3) | 171.0 (8.8) | 0.8 | 0.9 |
Weight (kg), Mean (SD) | 203 | 88.6 (22.1) | 84.1 (17.8) | 0.3 | 0.4 |
BMI (kg/m2), Mean (SD) | 203 | 30.2 (6.9) | 28.7 (5.7) | 0.2 | 0.3 |
BMI Category, n / N (%) | 203 | 0.7 | 0.8 | ||
< 20 | 3 / 143 (2.1%) | 2 / 60 (3.3%) | |||
20–25 | 31 / 143 (22%) | 14 / 60 (23.3%) | |||
25–30 | 49 / 143 (34%) | 23 / 60 (38.3%) | |||
> 30 | 60 / 143 (42%) | 21 / 60 (35.1%) | |||
SBP (mmHg), Mean (SD) | 203 | 129.4 (18.6) | 120.5 (19.8) | 0.001 | 0.003 |
DBP (mmHg), Mean (SD) | 203 | 76.9 (11.4) | 70.1 (11.4) | < 0.001 | < 0.001 |
BP Category, n / N (%) | 203 | 0.006 | 0.012 | ||
Normal | 35 / 143 (24.5%) | 29 / 60 (48.0%) | |||
Elevated | 22 / 143 (15.4%) | 10 / 60 (17.0%) | |||
Stage I Hypertension | 37 / 143 (25.9%) | 9 / 60 (15.0%) | |||
Stage II Hypertension | 49 / 143 (34.2%) | 12 / 60 (20.0%) | |||
No BP Measurement | 0 / 143 (0.0%) | 0 / 60 (0.0%) | |||
CKD Stage, n / N (%) | 203 | 0.022 | 0.039 | ||
G1 | 22 / 143 (15.0%) | 12 / 60 (20.0%) | |||
G2 | 48 / 143 (34.0%) | 13 / 60 (21.7%) | |||
G3a | 36 / 143 (25.0%) | 16 / 60 (26.7%) | |||
G3b | 27 / 143 (19.0%) | 6 / 60 (10.0%) | |||
G4 | 9 / 143 (6.3%) | 12 / 60 (20.0%) | |||
G5 | 1 / 143 (0.7%) | 1 / 60 (1.6%) | |||
Encephalopathy, n / N (%) | 203 | > 0.9 | > 0.9 | ||
No | 141 / 143 (98.6%) | 59 / 60 (98.3%) | |||
Yes | 2 / 143 (1.4%) | 1 / 60 (1.7%) | |||
Ascites, n / N (%) | 203 | < 0.001 | < 0.001 | ||
Not Present | 143 / 143 (100.0%) | 18 / 60 (30.0%) | |||
Present | 0 / 143 (0%) | 42 / 60 (70.0%) | |||
MELD Score, Mean (SD) | 197 | 10.4 (3.3) | 19.4 (8.6) | < 0.001 | < 0.001 |
(Missing, n) | 1 | 5 | |||
Hepatic Dysfunction, n / N (%) | 197 | < 0.001 | < 0.001 | ||
MELD ≤ 15 | 130 / 142 (91.5%) | 18 / 55 (33.0%) | |||
MELD > 15 | 12 / 142 (8.5%) | 37 / 55 (67.0%) | |||
(Missing, n) | 1 | 5 | |||
Child–Pugh Class, n / N (%) | 203 | < 0.001 | < 0.001 | ||
Class A | 143 / 143 (100.0%) | 6 / 60 (10.0%) | |||
Class B | 0 / 143 (0.0%) | 45 / 60 (75.0%) | |||
Class C | 0 / 143 (0.0%) | 9 / 60 (15.0%) | |||
Serum Creatinine (mg/dL), Mean (SD) | 203 | 1.36 (0.67) | 1.14 (0.61) | < 0.001 | 0.002 |
Serum Cystatin C (mg/L), Mean (SD) | 203 | 1.60 (0.65) | 1.68 (0.78) | 0.8 | 0.9 |
Serum albumin (g/dL), Mean (SD) | 202 | 4.20 (0.41) | 3.24 (0.58) | < 0.001 | < 0.001 |
(Missing, n) | 0 | 1 | |||
mGFR,f Mean (SD) | 203 | 62.5 (26.5) | 59.9 (31.5) | 0.3 | 0.4 |
eGFRcr(ASR),f Mean (SD) | 203 | 61.6 (26.9) | 77.3 (31.2) | < 0.001 | 0.002 |
eGFRcr(AS),f Mean (SD) | 203 | 64.3 (27.1) | 80.1 (30.9) | < 0.001 | 0.002 |
eGFRcr-cys(ASR),f Mean (SD) | 203 | 54.5 (24.2) | 61.5 (28.9) | 0.10 | 0.2 |
eGFRcr-cys(AS),f Mean (SD) | 203 | 56.8 (25.0) | 63.3 (29.6) | 0.2 | 0.2 |
GFRNMR,f Mean (SD) | 203 | 60.3 (23.5) | 59.2 (25.4) | 0.7 | 0.8 |